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Abstract
BACKGROUND: High antibiotics use in pediatric intensive care units (PICUs) results in antibiotic resistance, the 
unfavorable clinical outcome of patients, increase the length of hospital stay, and drug expenditure. 
AIM: This study aimed at setting clinical guidelines customized according to local diseases epidemiology and local 
cumulative antimicrobial susceptibility, implementing, and evaluating the Antimicrobial Stewardship Program (ASP) 
effect in; optimizing antibiotics use, decreasing antibiotics expenditure, decreasing the length of therapy and stay in 
hospitals, and improving patients’ clinical outcomes.
METHODS: A prospective study was conducted at a PICU of the Specialized Pediatric Hospital, Cairo University. 
Facility-specific guidelines were set, and the ASP was implemented and evaluated through the following indicators; 
adherence of physicians to the guidelines, ASP recommendations and acceptance of them, the rate of mortality, 
length of stay, drug costs, antibiotics days of therapy, and length of therapy.
RESULTS: The adherence to the ASP guidelines was positively correlated to the patient’s clinical outcome 
(p = 0.018). In post ASP period, the average length of stay and the length of therapy significantly decreased 
(p = 0.047, p = 0.001, respectively), the rate of adherence to the ASP guidelines was (91.9%), the days of therapy 
of ceftazidime, ceftriaxone, and amikacin decreased significantly (p = 0.041, p = 0.026, p = 0.004, respectively). The 
most common ASP recommendation was drug schedule/frequency change (26.1%) followed by drug discontinuation 
(17.8%) and the most common antibiotic required intervention was ampicillin-sulbactam (21.6%).
CONCLUSION: The antimicrobial stewardship is very effective in optimizing antibiotics use and leads to favorable 
outcomes in terms of decreased length of therapy, hospital stay, and mortality rate of the patients.
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Introduction
Antibiotics abuse in the pediatric intensive care 
unit (PICU) is very high [1]. About one-third of prescribed 
antibiotics are inappropriate resulting in antibiotic 
resistance, especially with lacking new antibiotics. Hence, 
the importance of antimicrobial stewardship arises which 
means judicious and optimized use of antibiotics and 
reducing the adverse effect of antibiotics [2].
General practitioners in primary care 
settings are common causes of antibiotic over-
prescription, which has been shown to increase the 
risk of reattendance and medicalization of self-limiting 
infectious diseases [3].
The utilization of antibiotics is not restricted 
only in health care settings. Agriculture, aquaculture, 
and farming consume a lot of antibiotics. The higher the 
antibiotic use, the higher the rate of resistance [4].
In 2014, the Centre for Disease Control and 
Prevention developed the core elements of a successful 
hospital Antimicrobial Stewardship Program (ASP) [5].
World Health Organization has reported that 
infections caused by resistant organisms are not only 
detected in developing countries but throughout the 
world [6].
Aim of the work
The aim of the study was to set clinical practice 
guidelines customized according to local epidemiology 
of diseases and local cumulative antimicrobial 
susceptibility and assess ASP implementation in the 
PICU.
Materials and Methods
This prospective study was conducted at 
the (PICU) in Specialized Pediatric Hospital, Cairo 
University (CUSPH), from April 1, 2016, to June 30, 
2017; pre-implementation phase from April 1, 2016, to 
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September 30, 2016, intervention phase from October 1, 
2016, to December 31, 2016, and post-implementation 
phase from January 1, 2017, to June 30, 2017.
The study was performed in the clinical 
microbiology department in collaboration with the 
departments of pediatrics and pharmacy at the 
specialized pediatric hospital, Cairo University (CUSPH).
Ethical approval
The study was ethically approved by the 
research ethics committee of the Faculty of Medicine, 
Cairo University.
Settings
This prospective study was conducted at 
PICU with 12 beds capacity (6 beds per room) and 
350 admissions per year in CUSPH which is a tertiary 
care teaching hospital. Staff of the unit working in 1:1 
care (1 nurse/1 patient) in unstable patients and 1:2 care 
(1 nurse/2 patients) in stable non-ventilated patients. 
All admissions during the period of each phase were 
included within the corresponding phase.
Flow of work
I. Data collection 
II. Metric Tools:
A- Antimicrobial Use:
1- Days of Therapy (DOT)
2- Length of therapy (LOT)
B- Outcome measures:
1- Clinical outcome of patient
2- Length of stay (LOS)
3- Drug costs
Pre ASP-implementaon Phase
Intervenon Phase
Construction of ASP and implementation of the 
antibiotic policy
Post-ASP-implementaon Phase  
I. Data collection 
II. Metric Tools:
A- Process measures:
1-Rate of adherence of clinicians to ASP 
policy
2- ASP recommendations
3- Rate of clinicians' acceptance of ASP 
recommendations
B- Antimicrobial Use:
1- Days of Therapy
2- Length of therapy
C- Outcome measures:
1-Clinical outcome of patient
2- Length of stay
3- Drug costs
Data collection included name, age, sex, 
weight, date of admission and discharge, pediatric risk 
of mortality score (PRISM III score), clinical diagnosis 
and outcome of the patient, and indication and proof 
of infection at the start of antibiotic therapy, 48 h and 
5 days reviews.
Construction of ASP
• Multidisciplinary team members and their job 
description
• Team leader: Organized and communicated 
all team members with the management 
to obtain adequate authority and was 
responsible for the expected outcomes of 
the ASP
• Physician: Mainstay of stewardship program 
implementation
• Clinical pharmacists: Responsible for 
pharmacy-driven interventions
• Clinical microbiologists: Provide clinical 
advice about microbiological investigations 
and construction of local cumulative annual 
antibiograms
• Infection control personnel: Monitored 
the healthcare-associated infections, 
antimicrobial resistance, and measures to 
prevent them
• Nurses: Implemented all elements of 
the ASP.
• Before program implementation, the 
antimicrobial stewardship strategic plans were 
presented and approved by the ASP team 
members and the head of the studied PICU, 
to ensure their acceptance. The support and 
collaboration of hospital administration were 
essential for the success of the program
• The ASP team members regularly met twice/
month to set policies that were applied in all 
situations for an optimal antibiotic prescription 
through:
• Documentation of dose, duration, and 
indication for all courses of antibiotics to be 
easily identifiable and accessible
• Development and implementation of 
facility-specific treatment policy based on 
national guidelines and local antimicrobial 
susceptibilities
• Reassessment of continuous need and choice 
of empiric antibiotics after 48 h of initiating 
antibiotics when more diagnostic information 
was available (antibiotic time outs)
• Regular education and training of staff 
groups on antibiotics use in the form of 
presentations in formal and informal settings 
and electronic communication
• PICU-specific antibiogram was constructed 
annually by microbiology laboratory staff 
members.
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patients treated according to the ASP policy to 
all patients admitted
2. ASP recommendations: Was measured by 
calculating the percent of each ASP recommendation 
given to all ASP recommendations
 ASP recommendations: Dose increase, 
decrease; drug change; drug formulation change; 
schedule/frequency change; discontinuation; add 
medication; other changes to therapy; education/
counseling session; change diluents; change 
final solution concentration; change infusion rate; 
laboratory monitoring; request other investigation; 
request cultures; or no recommendation [9].
3. Rate of clinicians’ acceptance to ASP 
recommendations: Was measured by 
calculating the percent of clinicians’ acceptance 
to implement the ASP recommendation to all 
ASP given recommendations.
Outcome measures
1. Clinical outcome of patients received ASP 
recommendations: Was measured by 
calculating the percent of discharge and deaths 
among patients received treatment according 
to the ASP recommendations
2. LOS was measured by dividing the total 
number of occupied hospital bed-days by the 
total number of admissions or discharges [10]
3. Drug costs were measured based on summing 
up the monthly dispensed amount of each 
antimicrobial during the study period [8].
Results
One hundred fifty-one patients were admitted to 
the PICU in the pre-implementation phase; 55.3% of them 
were males with a mean age of 32.12 ± 17.5 months old. 
Moreover, in the post-implementation phase, 161 patients 
were admitted, 54.7% were males with a mean age of 
24.53 ± 12 months old. The most common indication for 
antimicrobials in both phases was community-acquired 
pneumonia (45.3% and 58.3%, respectively). The percent 
of patients who received prophylactic antimicrobials 
significantly decreased from 25.2% pre-implementation to 
10% post-implementation (p = 0.002).
Process measures results
1. The rate of adherence of clinicians to ASP 
policy was 91.9%
2. ASP recommendations
 In the post-implementation phase, the most 
frequent antimicrobials required interventions 
were ampicillin-sulbactam (21.6%) followed 
After approval of the new guidelines by the ASP 
team, they were distributed to all PICU staff members to 
be ready for implementation.
The program was officially launched in April 1, 
2016 as the first ASP at PICU of CUSPH.
ASP implementation
Prior antimicrobial authorization
The clinician requested the ASP team for each 
targeted antimicrobial agent using prior authorization 
form. The ASP team reviewed cultures and sensitivities 
and the regimen of treatment. The ASP pre-approved 
certain indications for selected targeted antimicrobial 
agents. Approval for empiric use of certain antimicrobial 
agents was usually given for 48 h until the availability of 
the results of the cultures.
The antimicrobial prescription was classified 
into three groups according to the need of culture and 
prior approval as shown in Table 1:
Table 1: Antimicrobial prescription classification
Antimicrobials not requiring 
culture or prior approval
Antimicrobials requiring prior 
approval without culture
Antimicrobials requiring cultures 
and prior approval 
Amoxicillin/flucloxacillin
Amoxicillin/clavulanic acid
Ampicillin/sulbactam
Amikacin
Gentamicin
Acyclovir
Azithromycin
Cefobid
Ceftazidime
Ceftriaxone
Cefotaxime
Cefoperazone/sulbactam
Piperacillin/tazobactam
Amphotericin B
Fluconazole
Maxipime
Meropenem
Imipenem
Ertapenem
Ciprofloxacin
Levofloxacin
Tigecycline
Colistin
Vancomycin
Teicoplanin
Linezolid
Caspofungin
N.B.: Vancomycin, meropenem, 
and imipenem only dispensed 
empirically in case of sepsis
Metric tools
Antimicrobial use measures
DOT
Was measured by calculating any amount 
of a specific antimicrobial agent administered on a 
calendar day to a particular patient, as documented 
in the medication administration record. The day of 
admission, discharge, and transfer to and from locations 
was included in the day’s present count [7].
LOT
Was measured by calculating the number of 
days that a patient received systemic antimicrobials 
irrespective of their number and the total LOT of patients 
present during each phase was summed up [8].
Process measures
1. Rate of adherence of clinicians to ASP policy: 
Was measured by calculating the percent of 
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by imipenem (8.1%) and vancomycin (6.4%). 
The most frequent drug-related problem was 
dose calculation error (15.8%) followed by 
prescribing an unnecessary drug with no 
medical indication (13.5%). Moreover, the most 
frequent recommendation was drug schedule/
frequency change (26.1%) followed by drug 
discontinuation (17.8%).
3. The rate of acceptance to ASP 
recommendations among patients in the post-
implementation phase was 93.7%.
Antibiotic use measures
DOT 
DOT of antibacterial drugs as shown in table 
2 and DOT of all antimicrobials (antibacterial, antiviral, 
and antifungal) as shown in Table 3.
LOT
Significantly decreased from total 1502 days with 
mean 9.82 days pre-implementation to total 1318 days 
with mean 7.75 days post-implementation (p = 0.001).
Outcome measures results
Clinical outcome of patients
The percent of discharged patients was 
68.9% pre-implementation and increased to 75.2% 
post-implementation. While the percent of deaths was 
31.1% pre-implementation and decreased to 24.8% 
post-implementation (p = 0.203).
68.90%
31.10%
75.20%
24.80%
Discharge(improve) Death
Clinical outcome of patients
phase one phase two
LOS
The mean ± SD LOS was 10.66 ± 6.00 days 
pre-implementation and significantly decreased to 9.16 
± 5.00 days post-implementation (p = 0.047).
Drug costs
Drug costs significantly decreased by 19.66% 
from (68164.94 L.E.) pre-implementation to (54764.96 
L.E.) post-implementation (p = 0.01).
Discussion
ASP implementation in hospitals is mandatory, 
especially with steadily developing global antimicrobial 
resistance. The current study showed that the clinical 
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services most commonly interacting with the ASP 
post-implementation were pediatric respiratory service 
(40.4%) followed by neurological service (18.6%), 
while the clinical service most commonly interacting 
with the ASP in a study of Newland et al., 2012 was 
general pediatric/resident service (20%) followed by 
hematology/oncology (17%) and hospitalist (17%) [11].
The most common indication of antimicrobial 
intake was CAP (58.3%) followed by sepsis (26.7%) 
post-implementation. Newland et al., 2012 reported 
that the primary indications for antimicrobials included 
suspected sepsis (28%), fever, neutropenia (12%), and 
intra-abdominal infections (9%) [11].
The percent of prophylactic antimicrobial 
courses in our study decreased significantly 
post-implementation from 25.2% to 10% (p < 0.05), and 
this was the aim of the study to optimize antibiotics use 
to decrease antibiotics expenditure. This result agreed 
with the study of Stocker et al., 2012 who reported 
that the percent of prophylactic antimicrobial courses 
decreased significantly post-implementation from 
66.5% to 55.5% (p = 0.02) [12].
Unlike our results, ASP implementation at 
PICU in Agha Khan University Hospital showed that 
the rate of antimicrobial courses taken for prophylaxis 
did not change in the pre-implementation phase 43% 
versus the post-implementation phase 43.2% [1].
The most common ASP recommendation 
in this study was drug schedule/frequency change 
(26.1%) followed by drug discontinuation (17.8%) which 
are consistent with those reported by Di Pentima et al., 
2011 as the dose adjustment formed 40.2% of total 
recommendations (672 of 1673) while the modification of 
antimicrobial therapy formed 34.8% (583 of 1673) [13]. 
Other authors showed different recommendations; the 
most common was the modification of antimicrobial 
therapy which accounted for 48.5% in the study of 
Kreitmeyr et al., 2017, while in McCulloh et al. 2015 
study, it was the discontinuation of antibiotic (28.6%) and 
the most common antibiotic required recommendation 
was ceftriaxone (44%) [2], [14].
The most frequent antimicrobial required 
interventions in our study were ampicillin-sulbactam 
(21.6%) followed by imipenem (8.1%) and vancomycin 
(6.4%). Other studies, in the USA, showed different 
results, in Di Pentima et al., 2011 study the most frequent 
antimicrobial required interventions were vancomycin 
(16%) (268 of 1673), piperacillin-tazobactam (11%) 
(184 of 1673), ceftriaxone (6.3%) (105 of 1673), and 
fluconazole (5%) (82 of 1673) [13]. Newland et al., 2012 
reported that the most common antimicrobials reviewed 
by the ASP included ceftriaxone/cefotaxime (43%), 
vancomycin (18%), and ceftazidime (17%) of total 2378 
recommendations [11].
The rate of acceptance of ASP recommendations 
in our study was 93.7% among 349 recommendations 
indicating the raised awareness of clinicians toward the 
rationalized antibiotics use in this tertiary hospital with the 
high flow of patients and that was slightly higher than that 
reported by Di Pentima et al., 2011 and McCulloh et al., 2015 
which was 86.9% in both studies (total recommendations 
were 1637, 350 respectively), [13], [14] and it was 80% of 
total recommendations 2378 in a study of Newland et al., 
2012 [11].
The rate of acceptance of ASP 
recommendations in Kreitmeyr et al., 2017 study in 
German hospitals was slightly higher than in our study 
(95.8%) of total recommendations 167 [2].
The percent of patients received antimicrobials 
was 92.7% pre-implementation (151 patients) 
compared to 74.5% post-implementation (161 patients) 
(p < 0.001) indicating the beneficial effect of ASP in 
optimizing antibiotic use. Unlike our results, the impact 
of ASP in Kreitmeyr et al., 2017 study which revealed a 
minimal change in the percent of hospitalized children 
who received antimicrobials pre-implementation 
(30.6%) (1007 patients) versus post-implementation 
(30.5%) (967 patients) [2].
Our study showed the positive effect of the 
ASP in optimizing antibiotic use as all antibiotics; DOT 
decreased by 13.5%, with significant effect regarding 
ceftazidime, ceftriaxone, and amikacin. Other antibiotics 
DOT, including cephalosporins, aminopenicillins with 
beta-lactamase (ampicillin-sulbactam and amoxicillin-
clavulanic acid) piperacillin-tazobactam, meropenem, 
ciprofloxacin, all aminoglycosides, trimethoprim-
sulfamethoxazole, vancomycin, and metronidazole 
also showed reduction post-implementation (Table 2). 
Kreitmeyr et al. 2017 study showed a similar reduction 
in all antibiotic use by 10.5% post-implementation, 
this reduction was significant in 3rd generation 
cephalosporins (22.3%), fluoroquinolones (59.9%) 
(from 32 to 13 DoT/1000 PD), and metronidazole 
(51.1%) (from 27 to 13 DoT/1000 PD). However, they 
differ from our study in the consumption of combined 
aminopenicillins with beta-lactamase inhibitors as 
ampicillin-sulbactam and amoxicillin-clavulanic acid in 
which DOT significantly increased by 78.8% (from 17.1 
DoT/1000 PD to 30.5 DoT/1000 PD) [2].
Other studies reported similar effective ASP in 
a significant reduction of all antibiotics DOT/1000 PD 
in the ASP period includes Haque et al. study which 
reported reduction by 64% from 3477DOT/1000 PD 
to 1323DOT/1000 PD and Newland et al. study which 
reported reduction from 883 DOT/1000 PD to 787 
DOT/1000 PD [1], [11].
This study showed significantly increased DOT 
in gentamicin by 75.4% (from 23.3DOT/1000 PD to 94.7 
DOT/1000 PD ) (p = 0.009), unlike Di Pentima et al., 
2011 study which showed a significant reduction in 
the use of gentamicin (from 372 doses/1000 PD to 92 
doses/1000 PD) (p < 0.001) [13].
Unlike our results where carbapenem 
DOT/1000 PD showed a mild insignificant increase by 
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1.4% (from 225.6 DOT/1000 PD to 259.1 DOT/1000 PD), 
Horikoshi et al., 2017 Japan reported that carbapenem 
DOT/1000 PD significantly decreased by 59.3% (from 
4.94 DOT/1000 PD to 2.01 DOT/1000 PD) [15].
Certain antimicrobials consumption improved 
post-implementation, as the DOT of amphotericin B 
declined by 69% (from 35.5 DOT/ 1000 PD to 11 DOT/ 
1000 PD) (p = 0.485). Similarly, Di Pentima et al. 2011 
reported that amphotericin B was peaked at 50 doses 
pre-implementation versus 4 doses per 1000 patient 
days post-implementation (p < 0.0001) [13].
A comparison in average antibiotic use was 
done in the USA (9 hospitals implemented ASP and 
22 hospitals did not implement ASP). ASP+ hospital 
experienced a greater decline in all antibiotic use; (11%) 
versus (8%) in ASP- hospitals, (p = 0.04) [16].
The length of therapy in our study showed 
significant improvement which also denotes the positive 
effect of the ASP on antibiotic use (from 1502 days to 
1318 days) (p = 0.001). Similarly, Kreitmeyr et al., 2017 
study demonstrated a significant decline in overall LOT by 
7.7% (from 377.4 to 348.3 LOT/1000 PD) (p = 0.02) [2].
Similarly, the length of therapy decreased 
from 567 to 523 LOT per 1000 PD (p < 0.001) in 
Newland et al., 2012 [11].
The overall mortality in the current study 
decreased insignificantly from 31.1% (among 151 
patients) to 24.8% (among 161 patients). Similarly, 
Kreitmeyr et al., 2017 reported an insignificant difference 
regarding in-hospital mortality during pre- and post-
implementation periods (0.37% among 273 patients vs. 
0.38% among 263 patients, respectively) [2]. However, 
Horikoshi et al. 2017 reported a significant decrease 
(from 0.087/1000 PD to 0.051/1000 PD) in infection-
related mortality due to ASP’s positive effect on the 
clinical outcome of the patient.
In this work, the mean length of hospital stays 
showed a significant decline from mean 10.66 days to 
9.16 days post-implementation, giving this overcrowded 
tertiary hospital a better capacity to provide medical 
services for more patients. Comparable findings were 
reported by Horikoshi et al., 2017 (from mean 20.6 to 
18.6 days), [15] while Kreitmeyr et al. 2017 reported 
that the average length of stay remained stable with a 
median 7 days (range 1–93 days) versus 6 days (range 
2–123 days) [2].
Antimicrobial costs significantly reduced by 
19.66% (p = 0.01), which is consistent with the report 
of Haque et al., 2018, where the drug costs were 
significantly decreased by 58% (p < 0.0001) [1].
Table 2: DOT antibacterial drugs
Antibiotic Phase one – patient days=1804 Phase two – patient days=1648 Difference
DOT total DOT/1000PD % DOT total DOT/1000PD % p-value DOT/1000PD %
All (3rd + 4th) cephalosporins 271 150.2 9.7 153 92.8 6.9 0.093 ‒57.4 ‒38.2
3rd cephalosporins 267 148 9.5 122 74 5.5 0.065 ‒74 ‒50
Ceftazidime 60 33.3 2.1 4 2.4 0.2 0.041 ‒30.9 ‒92.8
Ceftriaxone 161 89.2 5.7 51 31 2.3 0.026 ‒58.2 ‒65.2
Cefotaxime 46 25.5 1.6 67 40.7 3 0.937 15.2 37.3
4th cephalosporins 4 2.2 0.1 31 18.8 1.4 0.310 16.6 88.3
All combinations 605 335.4 21.6 380 230.6 17.1 0.180 ‒104.8 ‒31.2
Amoxicillin/clavulanic acid + Ampicillin/sulbactam 424 235 15.1 292 177.2 13.2 0.394 ‒57.8 ‒24.6
Amoxicillin/clavulanic acid 29 16.1 1 0 0 0 0.065 ‒16.1
Ampicillin/sulbactam 395 219 14.1 292 177.2 13.2 0.485 ‒41.8 ‒19.1
Cefoperazone/sulbactam 0 0 0 18 11 0.8 0.699 11
Piperacillin/tazobactam 181 100.3 6.4 70 42.5 3.2 0.180 ‒57.8 ‒57.6
All carbapenems 407 225.6 14.5 427 259.1 19.2 0.485 33.5 1.4
Imipenem 87 48.2 3.1 154 93.4 6.9 0.394 45.2 48.4
Meropenem 320 177.4 11.4 239 145 10.8 0.485 ‒32.4 ‒18.3
Ertapenem 0 0 0 34 20.6 1.5 0.180 20.6
All fluoroquinolones 262 145.2 9.3 306 185.7 13.8 0.065 40.5 21.8
Ciprofloxacin 229 127 8.2 187 113.5 8.4 0.818 ‒13.5 ‒10.6
Levofloxacin 33 18.3 1.2 119 72.2 5.4 0.026 53.9 74.7
All aminoglycosides 443 245.6 15.8 270 163.8 12.2 0.485 ‒81.8 ‒33.3
Amikacin 401 222.3 14.3 114 69.2 5.3 0.004 ‒153.1 ‒68.9
Gentamycin 42 23.3 1.5 156 94.7 7 0.009 71.4 75.4
Trimethoprim/sulfamethoxazole 116 64.3 4.1 31 18.8 1.4 0.240 ‒45.5 ‒70.8
Polymyxin B 99 54.9 3.5 121 73.4 5.5 0.589 18.5 25.2
Tigecycline 13 7.2 0.5 13 7.9 0.6 0.699 0.7 8.9
Neomycin 7 3.9 0.2 31 18.8 1.4 0.589 14.9 79.3
Metronidazole 122 67.6 4.3 70 42.5 3.2 0.485 ‒25.1 ‒37.1
Vancomycin 349 193.6 12.4 179 108.6 8.1 0.132 ‒85 ‒43.9
Teicoplanin 18 10 0.6 27 16.4 1.2 0.065 6.4 40.1
Erythromycin 86 47.7 3.1 119 72.2 5.4 0.394 24.5 33.9
Clindamycin 9 5 0.3 92 55.8 4.1 0.026 50.8 91
All antibiotics 2807 1556 100 2219 1346.4 100 0.394 ‒209.6 ‒13.5
Table 3: DOT – all antimicrobials (antibacterial, antiviral, and anti-fungal drugs)
Antimicrobial Phase one – patient days=1804 Phase two – patient days=1648 Difference
DOT total DOT/1000PD % DOT total DOT/1000PD % p-value DOT/1000PD %
All antibiotics 2807 1556 88.1 2219 1346.4 90.1 0.394 ‒209.6 ‒13.5
Acyclovir 100 55.4 3.1 149 29.7 6 0.394 ‒25.7 ‒46.4
Tamiflu 8 4.4 0.3 9 5.5 0.4 0.818 1.1 20
Amphotericin B 64 35.5 2 18 11 0.7 0.485 ‒24.5 ‒69
Fluconazole 206 114.2 6.5 157 95.3 6.4 1.000 ‒18.9 ‒33.9
Mycamine 0 0 0 12 7.3 0.5 0.394 7.3
All antimicrobials 3185 1765.5 100 2464 1495.1 100 0.180 ‒270.4 ‒15.3
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Conclusion and Recommendations
The ASP is very important and very effective in 
optimizing and improving the antibiotic use to reach the 
best clinical outcome of the patients and to decrease 
hospital length of stay and drug costs.
Considering the relatively small population 
study and the short period of observation, lack of 
financial resources, lack of effective IT electronic 
system linking the multidisciplinary departments 
together, we recommend ASP implementation over 
a larger population and hospital settings with more 
comprehensive administration involvement that could 
afford financial resources and commit all departments 
to the ASP.
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